Company's Profile
Zenyth Therapeutics Pty Ltd develops and commercializes antibody-based therapies in the areas of inflammation and cancer. The company develops monoclonal antibodies, which target the interleukin-13 (IL-13) receptor alpha1 submits to inhibit IL-13 activity as a novel approach for treating asthma and other respiratory diseases. It also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit; GM-CSFRa, for potential therapeutic use in inflammatory diseases, such as rheumatoid arthritis; and develops antibody inhibitors of vascular endothelial growth factor (VEGF)-B for use in the treatment of cancer and rheumatoid arthritis. In addition, the company develops various earlier stage products, such as VEGF-B gene and protein; suppressors of cytokine signaling; and epidermal growth factor receptor inhibitor. It has partnerships with Merck and Co., Inc.; Cambridge Antibody Technology; and MuriGen Therapeutics and Medarex, Inc. Zenyth Therapeutics Pty Ltd was formerly known as Zenyth Therapeutics Limited and changed its name to Zenyth Therapeutics Pty Ltd in November 2006. The company was founded in 1986 and is based in Richmond, Australia. Zenyth Therapeutics Pty Ltd operates as a subsidiary of CSL Limited.